Top Biotech Companies in Dublin (42)
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments...
BioMarin Pharmaceutical Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Results show double‑digit revenue growth in 2025, with acceleration in Q4 driven by Voxzogo uptake and steady enzyme therapies across 55 markets. 2026 guidance points to a higher revenue range, indicating continued expansion.
Profitability: Disclosures highlight strong profitability with $828 million in 2025 operating cash flow and a targeted ~40% non‑GAAP operating margin for 2026 (excluding Amicus). Non‑GAAP EPS guidance of $4.95–$5.15 further signals operating leverage.
Diversified Revenue Streams: The portfolio spans multiple enzyme therapies and the achondroplasia franchise, and the pending Amicus acquisition would add Galafold and Pombiliti + Opfolda to diversify revenues from mid‑2026 onward. Enzyme therapies collectively grew in 2025, supporting breadth beyond a single asset.
PTC is a patient-centered biopharmaceutical company focused on discovering, developing & commercializing medicine for patients with rare and serious disease
Alkermes focuses on the development of innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction, and cancer. As a fully-integrated, global biopharmaceutical company, we apply our scientific expertise and proprietary technologies to develop products that are designed to make a meaningful difference in the way patients manage their disease. We are inspired by some...
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we...
Regeneron's Top Stability & Growth Strengths
Product Line Growth: The company is growing on financials and products, with momentum attributed to EYLEA HD, Libtayo, and rising Dupixent collaboration revenue alongside shareholder-return actions (dividend and buybacks) reinforcing the trend in 2024–2025.
Future-Ready Strategy: The setup for 2025–2026 includes multiple identified catalysts, including the odronextamab FDA decision (target action date July 30, 2025), further EYLEA HD label/formulation updates, and the ongoing Dupixent COPD rollout as key determinants for sustaining or accelerating growth.
Innovation-Driven Growth: A science-driven platform approach (including VelocImmune, the Regeneron Genetics Center, and advanced proteomics/genomics) is positioned as enabling rapid therapeutic discovery across multiple therapeutic areas, supporting an ongoing pipeline-led growth thesis.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
ICON plc's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is positioned as a top-tier global CRO with significant scale and a broad geographic footprint, supported by a major acquisition that strengthened its competitive standing. Operational activity indicators and industry recognition are presented as reinforcing its ability to win and execute large, complex trials.
Profitability: Earnings and operating profit metrics are described as improving in 2024, with increases in GAAP net income, adjusted earnings per share, and adjusted EBITDA. These results suggest the business maintained solid margin performance even as quarterly revenue fluctuated.
Resilient & Sustainable Growth: A large backlog and a book-to-bill above 1.0 in 2024 are cited as providing multi-year revenue visibility and demand coverage. Continued backlog levels into 2025 are described as a stabilizing factor despite a softer near-term revenue trajectory.
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
AstraZeneca's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising strongly, with 2024 up to $54.1B and continued momentum into 2025 alongside management’s stated 2030 ambition. The trend is broad‑based across oncology and biopharma, with repeated beats and reaffirmed guidance supporting durability.
Strong Market Position & Advantage: Market position is top‑tier globally by value and leadership is pronounced in oncology, where the company ranks among the top three by revenue with multiple anchor assets. Scale and execution in the U.S. and other key markets underline competitive advantage.
Innovation-Driven Growth: Pipeline and approvals are driving expansion, with multiple 2025 U.S. FDA wins for ADCs, an expanded first‑line label for Enhertu, and a deep ASCO 2025 presence across ADC, I/O, targeted agents, and SERD.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
Cellix is dedicated to providing our customers with easy-to-use benchtop instruments for cell analysis, cell sorting and customised solutions for microfluidics. Cellix was spun-out from Trinity College Dublin in 2006 when we launched our VenaFlux and Microfluidic Solutions ranges. Over the years, we have expanded our product offerings supporting our customers in several therapeutic areas including thrombosis, oncology, atherosclerosis, inflammation,...
Founded in 1996, PSC Biotech Corporation was created with the vision of providing life science companies unmatched support. To date, PSC Biotech Corporation now serves 1000 clients in more than 35 countries worldwide through professional services consulting, cloud-based software solutions, pharmaceuticals contract manufacturing, life science investment consulting, and metrology services. PSC Biotech Corporation has six unique divisions within the parent company...
MMS is an award-winning, global clinical research organization (CRO) that supports leading pharmaceutical and biotech companies as well as many smaller enterprises across our spectrum of services. Having completed more than 50 submissions for drug approval over the last 5 years, we remain a top choice for sponsors who are looking for innovation and demand high quality from their CRO...
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
Zymeworks (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials...
Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new...
Genuity Science is a data sourcing, analytics, and insights organization that partners with global biopharma companies to provide deep end-to-end discovery services. Using purpose-driven data, genomic know-how, and an advanced AI/ML platform, the company catalyzes insights in CNS, cardiometabolic, and inflammatory diseases to accelerate drug discovery and improve precision medicine and patient quality of life globally.
GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders
Avadel (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once...
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers...
Opsona Therapeutics is a leading drug development company specialising in the human immune system. Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline...
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development...
